Gland Pharma Limited has reported a 6% increase in revenue for the second quarter of fiscal year 2026 (Q2FY26), reaching ₹14,869 million compared to ₹14,058 million in the same quarter last year. The company's total income also saw a rise of 7%, amounting to ₹15,710 million, driven by a 41% surge in other income to ₹842 million. Despite a slight 1% decrease in revenue from the previous quarter (Q1FY26), Gland Pharma demonstrated strong performance in gross profit, which climbed 12% year-on-year to ₹9,331 million, yielding a gross profit margin of 63%.

In terms of profitability, Gland Pharma’s EBITDA for Q2FY26 was reported at ₹3,139 million, an increase of 6% from the prior year, with an EBITDA margin remaining steady at 21%. The adjusted EBITDA, which accounts for stock option compensation and one-off GST-related provisions, rose 13% to ₹3,355 million, further enhancing the company's operational performance. The profit before tax (PBT) also improved by 11% year-on-year to ₹2,839 million, with a PBT margin of 19%.

Net profit after tax (PAT) for the quarter reached ₹1,837 million, reflecting a 12% growth compared to ₹1,635 million in Q2FY25, although it showed a 15% decline from the previous quarter. The PAT margin remained consistent at 12%. For the six-month period ending September 2025, Gland Pharma reported a 7% revenue increase, totaling ₹29,925 million, alongside an impressive 30% growth in PAT to ₹3,992 million. The company’s performance amidst challenging market conditions underscores its resilience and effective operational strategies.